ATTACHMENT 1 ▇▇▇▇▇▇▇ ▇▇▇▇▇ definition
ATTACHMENT 1 ▇▇▇▇▇▇▇ ▇▇▇▇▇. The Texas Tech-HemoBioTech Joint Blood Substitute Project. Phase II: U.S. Patent Extension and Initial IND Stage. PROJECT DIRECTOR (at HemoBioTech, Inc.): Dr. Arthur P. Bollon PROJECT PRINCIPAL INVESTIGATOR (at TTUHSC): ▇▇. Jan Simoni DETAILED BUDGET FOR PHASE II OF THE PROJECT FROM: D▇▇▇▇▇▇▇ ▇, 2004 THROUGH: November 30, 2005/(1) SALARY: NAME ROLE ON TYPE % DOLLAR AMOUNT REQUESTED PROJECT APPT EFF SALARY SALARY FRINGE TOTAL (mo) BASE REQUESTED SOMONI, Jan P.I. * *% * * * * MOELLER, John F. Post-doc * *% * * * * SIMONI, Grace Med. Res. * *% * * * * To be hired Animal Tech. * *% * * * * SALARY SUBTOTALS: * * * CONSULTANTS * * * EQUIPMENT (Itemize): * Phase II of this project will not require any equipment above $*. However, modern computer (laptop) is needed for data collection and acquisition: SUPPLIES: (Itemize by category): * * * * * * * * * * * * * * * * * * * * * * TOTAL (including computer) ALTERATIONS AND RENOVATIONS: Renovation and sanitation the Texas Tech Blood Substitute Production Facility: * (the exact cost will be determined later) Renovation/remodeling of the Animal Blood Donor Facility (New Deal Farm): * (Cattle Facility Option 2) OTHER EXPENSES: Photocopying, postage, phone, secretarial, e-mail/internet connection: * (Cost of the CMC, pre-clinical, clinical research data transfer into the pdf file presented separately as Attachment 2) TRAVEL: For P.I. and co-investigators to travel to company headquarter, FDA, etc.: * SUBTOTAL DIRECT COST FOR PHASE II OF THE PROJECT: * TTUHSC OVERHEAD (25% of 158,002 base-excluding alterations/renovations) * TOTAL FOR PHASE II: 230,503 /(1) THIS BUDGET REFLECTS THE PROJECT I, III, IV AND V AND IS NOT YET RELATED TO * FROM THIS BUDGET, HOWEVER, CERTAIN * ACTIVITIES WILL BE CONDUCTED (I.E., ADDITIONAL * TESTS, EVALUATION OF A NEW METHOD FOR *, DETECTION OF * IN HEMOTECH(TM), ETC). THE EXACT COST OF THE PROJECT II (TRANSFER OF THE *, PRE-CLINICAL AND CLINICAL RESEARCH DATA INTO PDF FORMAT) IS PRESENTED AS ATTACHMENT 2 AND FUNDS WILL BE TRANSFERRED DIRECTLY FROM HEMOBIOTECH, INC. TO EM CENTER AT TTUHSC(W/O OVERHEAD). * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.